Apigenin’s reputation is built almost entirely on calm and sleep — the GABA-A binding story that explains chamomile tea. Depression research is a separate line of work with a different set of mechanisms, and it’s worth separating because the two aren’t the same claim. Anxiolytic activity does not imply antidepressant activity, and in apigenin’s case the depression studies point at dopamine, inflammasome signaling, and monoamine oxidase rather than the benzodiazepine site. Here’s what three decades of rodent work has actually measured.
Key Takeaways
- A 2003 study found injected apigenin reduced immobility in the forced swim test at 12.5 and 25 mg/kg — and the effect was blocked by haloperidol, a dopamine D2 antagonist, implicating dopamine rather than GABA.
- The same study found the effect disappeared at 100 mg/kg, an inverted-U dose response that argues against “more is better.”
- A 2016 rat study using chronic unpredictable mild stress reported apigenin restored sucrose preference and activity, working through PPAR-gamma upregulation that suppressed the NLRP3 inflammasome and IL-1 beta.
- A 2023 mouse study found apigenin inhibited monoamine oxidase A activity in the hippocampus and prefrontal cortex — the same enzyme class targeted by an older category of antidepressant drugs.
- All three used injected or gavage dosing in rodents. There is no human trial of apigenin for depression, and the MAO-A finding raises a real interaction concern rather than a reason for enthusiasm.
The Original Finding: Dopamine, Not GABA
The foundational study dates to 2003, when researchers at Tohoku Pharmaceutical University tested apigenin isolated from Perilla frutescens in the mouse forced swim test, a standard behavioral despair screen. Intraperitoneal apigenin at 12.5 and 25 mg/kg significantly decreased immobility time. Then they did the part that makes the study useful: they measured monoamine turnover across seven brain regions, and they tested what happened when they blocked specific receptors.
Apigenin at 25 mg/kg attenuated the swim-stress-induced changes in dopamine turnover in the amygdala and hypothalamus. And critically, pretreatment with haloperidol — a dopamine D2 antagonist — abolished apigenin’s effect on immobility entirely.[1] That is a mechanistic dissociation worth noting: the anxiolytic effects of apigenin are attributed to GABA-A receptor binding, but this antidepressant-like effect appears to run through dopaminergic signaling instead.
One more detail from that paper deserves attention because it’s routinely omitted. At 100 mg/kg, immobility returned to control levels — the effect vanished at the highest dose tested.[1] A non-monotonic dose response like that is a warning against the assumption that a higher supplement dose produces a stronger effect.
The Inflammation Route: PPAR-gamma and the NLRP3 Inflammasome
A 2016 study in Behavioural Brain Research took a different angle, working from the inflammatory hypothesis of depression. Rats were subjected to chronic unpredictable mild stress, a model that produces the reduced sucrose consumption and lowered locomotor activity used as rodent analogues of anhedonia. Apigenin at 20 mg/kg by gavage for three weeks substantially reversed both.
The mechanism they traced runs through the prefrontal cortex, where chronic stress activated the NLRP3 inflammasome and raised IL-1 beta. Apigenin upregulated PPAR-gamma, which downregulated NLRP3, which lowered IL-1 beta production. The causal step was tested directly: GW9662, a selective PPAR-gamma inhibitor given 30 minutes before apigenin, diminished apigenin’s effect on the inflammasome.[2] That’s a mechanism established with a blocking experiment rather than mere correlation, which is a meaningfully higher standard than most preclinical supplement research meets.
The MAO-A Finding, and Why It’s a Caution as Much as a Result
A 2023 study in chronically stressed mice reported that apigenin reversed anhedonia and reduced immobility time, lowered brain corticosterone and malondialdehyde, raised glutathione and superoxide dismutase, and attenuated IL-6 and TNF-alpha. The headline mechanism was inhibition of monoamine oxidase A activity in the hippocampus and prefrontal cortex, supported by molecular docking that put apigenin’s binding affinity for MAO-A at -7.7 kcal/mol, stronger in the model than the reference inhibitor clorgyline at -6.8.[3]
Monoamine oxidase inhibitors are a real antidepressant class, so this reads as a validating result. It also reads as a flag. MAOIs carry the most demanding interaction profile of any antidepressant category — combined with SSRIs, SNRIs, triptans, or certain other serotonergic agents, MAO inhibition contributes to serotonin syndrome risk. A docking score in a mouse study is not evidence that a supplement dose produces clinically meaningful MAO-A inhibition in a person. But it is exactly the sort of finding that argues for talking to a prescriber before stacking apigenin on top of psychiatric medication, not for treating it as a natural alternative to one. Apigenin also inhibits several cytochrome P450 enzymes involved in drug metabolism, which compounds the point.
What’s Missing
The gap is the same one that limits nearly every apigenin claim: no human trial. Three rodent studies across three mechanisms is a reasonable preclinical foundation and a completely inadequate basis for treating depression. Two of the three used intraperitoneal injection, bypassing the poor oral absorption that characterizes free apigenin. Rodent forced-swim and sucrose-preference measures are screening tools for compounds that might warrant human study, not proxies for clinical depression, which involves cognitive and affective dimensions those tests cannot capture.
Depression is a serious condition with treatments that have been tested in tens of thousands of people. If you’re experiencing persistent low mood, loss of interest, or thoughts of self-harm, that warrants a clinician, not a supplement decision. Apigenin has no established role in treating it.
Bottom Line
Three rodent studies report antidepressant-like effects from apigenin through three distinct mechanisms: dopaminergic signaling (confirmed by haloperidol blockade), PPAR-gamma-mediated suppression of the NLRP3 inflammasome (confirmed by PPAR-gamma blockade), and monoamine oxidase A inhibition. The mechanistic work is better-controlled than typical supplement research. It is also entirely preclinical, mostly injected, and non-monotonic in dose. The MAO-A result in particular is a reason for caution around drug interactions, not a reason to treat apigenin as an antidepressant.
References
- Nakazawa T, Yasuda T, Ueda J, Ohsawa K. Antidepressant-like effects of apigenin and 2,4,5-trimethoxycinnamic acid from Perilla frutescens in the forced swimming test. Biological & Pharmaceutical Bulletin (2003). PMID 12673028
- Li R, Wang X, Qin T, Qu R, Ma S. Apigenin ameliorates chronic mild stress-induced depressive behavior by inhibiting interleukin-1beta production and NLRP3 inflammasome activation in the rat brain. Behavioural Brain Research (2016). PMID 26416673
- Olayinka JN, Akawa OB, Ogbu EK, et al. Apigenin attenuates depressive-like behavior via modulating monoamine oxidase A enzyme activity in chronically stressed mice. Current Research in Pharmacology and Drug Discovery (2023). PMID 37501771
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
